Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hSTC810 + paclitaxel
- Development stage
- Discontinued
- Lead developer
- STCube
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
hSTC810 + paclitaxel is a combination therapy under investigation for the treatment of relapsed or refractory extensive stage small cell lung cancer. hSTC810 (also known as nelmastobart or STT-003) is a bispecific antibody that targets immune checkpoints to enhance antitumor activity and potentially overcome resistance in various cancers. Paclitaxel is a well-established chemotherapy agent classified as a mitotic inhibitor; it works by inhibiting cell division through stabilization of microtubules, thereby blocking cancer cell proliferation. The combination aims to leverage the immunomodulatory effects of hSTC810 with the cytotoxic action of paclitaxel for improved efficacy in difficult-to-treat cancers such as small cell lung cancer[1][2][3][5][6][7].
- Brand names
- TaxolOnxol
02
Targets
Checkpoint (Immune checkpoints)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on hSTC810 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hSTC810 + paclitaxel.